Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 967-974

  Gismondi, Ronaldo A O C ^a   Oigman, Wille ^a   Bedirian, Ricardo ^a   Pozzobon, Cesar R ^a   Ladeira, Marcia C Boaventura ^a   Neves, Mario F ^a  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Benazepril; Blood pressure; C reactive protein; Comparison study; Diabetes mellitus; Endothelium; Hypertension; Losartan; Renin angiotensin system; Vascular stiffness; Vasodilation

Indexed keywords

BENAZEPRIL; BENZAZEPINE DERIVATIVE; C REACTIVE PROTEIN; LOSARTAN; AMLODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SALICYLIC ACID; SULFONYLUREA;

AORTA; ARTERIAL STIFFNESS; BLOOD PRESSURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; ADULT; AGED; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY PULSE; CLINICAL ARTICLE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIAL ARTERY; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

AORTA; BENZAZEPINES; BLOOD PRESSURE; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS;

EID: 84952951462     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320315573681     Document Type: Article

References (45)

1. Pieske B and Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol 2008; 23: 340-349.
2. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013; 34: 3035-3087.
3. Gordon-Dseagu VLZ, Shelton N and Mindell J. Diabetes mellitus and mortality from all causes, cancer, cardiovascular and respiratory disease: Evidence from the Health Survey for England and Scottish Health Survey cohorts. J Diabet Complicat 2014; 28: 791-797.
4. Romon I, Rey G, Mandereau-Bruno L, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes: The 2001-2006 ENTRED cohort. Diabet Med 2014; 31: 946-953.
5. Inaba Y, Chen JA and Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imag 2010; 26: 631-640.
6. Vlachopoulos C, Aznaouridis K and Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327.
7. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830-834.
8. Matsuura E, Hughes GRV and Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008; 7: 558-566.
9. Schmieder RE, Hilgers KF, Schlaich MP, et al. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
10. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
11. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Ass 2014; 311: 507-520.
12. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-( 1-7): An evolving story in cardiovascular regulation. Hypertension 2006; 47: 515-521.
13. Miyamoto M and Kotani K. The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients. Int J Vasc Med 2012; article ID 453264.
14. Li S, Wu Y, Yu G, et al. Angiotensin II receptor blockers improve peripheral endothelial function: A meta-analysis of randomized controlled trials. PLoS One 2014; 9: e90217.
15. Shahin Y, Khan JA, Samuel N, et al. Angiotensin converting enzyme inhibitors' effect on endothelial dysfunction: A meta-analysis of randomised controlled trials. Atherosclerosis 2011; 216: 7-16.
16. Charakida M, Masi S, Luscher TF, et al. Assessment of atherosclerosis: The role of flow-mediated dilatation. Eur Hear J 2010; 31: 2854-2861.
17. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
18. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Hear J 2006; 27: 2588-2605.
19. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with Type 2 diabetes and hypertension. J Hypertens 2007; 25: 785-791.
20. Robles NR, Cerezo I and Hernandez-Gallego R. Reninangiotensin system blocking drugs. J Cardiovasc Pharmacol Ther 2014; 19: 14-33.
21. Ferrario CM and Strawn WB. Role of the renin-angiotensinaldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128.
22. Lévy BI. Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8-13.
23. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
24. Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 2005; 23: 435-444.
25. Schram MT, Van Ittersum FJ, Spoelstra-De Man A, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive Type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429-437.
26. Koulouris S, Symeonides P, Triantafyllou K, et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with Type 2 diabetes mellitus. Am J Cardiol 2005; 95: 1386-1388.
27. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007; 115: 2390-2397.
28. Inaba Y, Chen JA and Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imag 2010; 26: 631-640.
29. Bruno RM, Penno G, Daniele G, et al. Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. Diabetologia 2012; 55: 1847-1855.
30. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
31. Yilmaz MI, Carrero JJ, Martín-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in Type 2 diabetic hypertensive patients with proteinuria: Effects on soluble TWEAK, PTX3 and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5: 1174-1181.
32. Mullen MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized, double-blind study. J Am Coll Cardiol 1998; 31: 1330-1335.
33. Trevelyan J, Needham EWA, Morris A, et al. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. Heart 2005; 91: 1053-1057.
34. Bots ML, Remme WJ, Lüscher TF, et al. ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007; 21: 269-279.
35. Vlachopoulos C, Aznaouridis K and Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327.
36. Shahin Y, Khan JA and Chetter I. Angiotensin converting enzyme inhibitors' effect on arterial stiffness and wave reflections: A meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012; 221: 18-33.
37. Ali K, Rajkumar C, Fantin F, et al. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manag 2009; 5: 587-592.
38. Rehman A, Ismail SB, Naing L, et al. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007; 20: 184-189.
39. Mahmud A and Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-325.
40. Topouchian J, El Feghali R, Pannier B, et al. Arterial stiffness and pharmacological interventions: The Transcend Arterial Stiffness Substudy (TRANS study). Vasc Health Risk Manag 2007; 3: 381-387.
41. Rajzer M, Klocek M and Kawecka-Jaszcz K. Effect of amlodipine, quinapril and losartan on pulse wave velocity and plasma collagen markers in patients with mildto- moderate arterial hypertension. Am J Hypertens 2003; 16: 439-444.
42. Mitchell GF, Hwang S-J, Vasan RS, et al. Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation 2010; 121: 505-511.
43. Kaess BM, Rong J, Larson MG, et al. Aortic stiffness, blood pressure progression and incident hypertension. J Am Med Ass 2012; 308: 875-881.
44. Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst 2001; 2: S8-11.
45. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in Type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617-1623.